EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY 4.0

Clinical Effectiveness of Tislelizumab With Gemcitabine/Cisplatin Versus Gemcitabine/Cisplatin Alone as Adjuvant Therapy for High‐Risk Muscle‐Invasive Urothelial Carcinoma: A Real‐World Study

Yanjun Wang iD, Kaihua Zhong, Xingliang Tan, Qianghua Zhou, Lijuan Jiang, Kai Yao, Zhiming Wu iD

Cancer Medicine · 2025

DOI: 10.1002/cam4.70661 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Cancer Medicine, 2025. Verfasst von Yanjun Wang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Sun Yat-Sen University Cancer Center, Guangzhou, China. Hauptthemen laut MEDLINE: Deoxycytidine, Antineoplastic Combined Chemotherapy Protocols, Antibodies, Monoclonal, Humanized, Urinary Bladder Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Muscle‐invasive urothelial carcinoma (MIUC) is a highly aggressive cancer associated with poor prognosis. Despite advancements in treatment, the optimal therapeutic approach remains unclear. Immune checkpoint inhibitors, when added to chemotherapy, have shown promise in improving patient outcomes.

Aims

This study aimed to evaluate the efficacy and safety of adjuvant tislelizumab combined with gemcitabine/cisplatin (Tisle+GC) compared to GC alone in patients with high‐risk MIUC. Materials & Methods We conducted a retrospective analysis of 117 patients with histologically confirmed pT3/4 and pN+ MIUC treated at our center between October 2016 and March 2023. Eligible patients received either Tisle+GC or GC alone, excluding those with prior neoadjuvant therapy. We compared disease‐free survival (DFS), overall survival (OS), and treatment‐related adverse events (AEs) between the two groups using Cox proportional hazards models and Kaplan–Meier estimates.

Results

The Tisle+GC group showed significantly longer median DFS (19.08 vs. 9.06 months, HR = 0.114, p < 0.001) and OS (20.07 vs. 10.63 months, HR = 0.083, p = 0.026) compared to the GC group. Nerve tract invasion was identified as a significant predictor of poor outcomes (HR = 22.1, p = 0.003). Both groups experienced manageable grade 1–2 immune‐related AEs, with pruritus being the most common, followed by liver function abnormalities and thyroid disturbances. Nonhematologic toxicities in the Tisle+GC group included elevated aspartate aminotransferase and hyponatremia, while the GC group mainly reported vomiting. No treatment‐related fatalities occurred.

Discussion

The addition of tislelizumab to GC chemotherapy significantly improved both DFS and OS in high‐risk MIUC patients. The safety profile was manageable, with immune‐related AEs being predictable and not life‐threatening. The findings support the potential of Tisle+GC as an effective adjuvant therapy.

Conclusion

Tisle+GC is a promising adjuvant treatment for high‐risk MIUC, offering improved survival outcomes with a manageable safety profile. Further prospective studies are needed to confirm these results and establish the long‐term benefits of this combination therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DeoxycytidineAntineoplastic Combined Chemotherapy ProtocolsAntibodies, Monoclonal, HumanizedUrinary Bladder NeoplasmsCarcinoma, Transitional CellHumansMaleGemcitabineFemaleCisplatinAgedMiddle AgedRetrospective StudiesChemotherapy, AdjuvantNeoplasm InvasivenessAdultTreatment Outcome

Stichwörter der Autor:innen

cisplatindisease‐free survivalgemcitabinemuscle‐invasive urothelial carcinomaoverall survivaltislelizumab

Substanzen

GemcitabineDeoxycytidineCisplatintislelizumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Urology, Sun Yat-Sen University Cancer Center, Guangzhou, China.
  • Department of Urology, Meizhou People's Hospital, Meizhou, China.

ORCID-Profile: Yanjun Wang, Zhiming Wu

Zitieren

APA

Wang, Y., Zhong, K., Tan, X., Zhou, Q., Jiang, L., Yao, K., & Wu, Z. (2025). Clinical Effectiveness of Tislelizumab With Gemcitabine/Cisplatin Versus Gemcitabine/Cisplatin Alone as Adjuvant Therapy for High‐Risk Muscle‐Invasive Urothelial Carcinoma: A Real‐World Study. Cancer Medicine. https://doi.org/10.1002/cam4.70661

Vancouver

Wang Y, Zhong K, Tan X, Zhou Q, Jiang L, Yao K, et al. Clinical Effectiveness of Tislelizumab With Gemcitabine/Cisplatin Versus Gemcitabine/Cisplatin Alone as Adjuvant Therapy for High‐Risk Muscle‐Invasive Urothelial Carcinoma: A Real‐World Study. Cancer Medicine. 2025. doi:10.1002/cam4.70661

BibTeX
@article{Wang2025,
  author = {Wang, Yanjun and Zhong, Kaihua and Tan, Xingliang and Zhou, Qianghua and Jiang, Lijuan and Yao, Kai and Wu, Zhiming},
  title = {Clinical Effectiveness of Tislelizumab With Gemcitabine/Cisplatin Versus Gemcitabine/Cisplatin Alone as Adjuvant Therapy for High‐Risk Muscle‐Invasive Urothelial Carcinoma: A Real‐World Study},
  journal = {Cancer Medicine},
  year = {2025},
  doi = {10.1002/cam4.70661}
}
Kostenlos starten →